Wei Chieh Pung
Breast Regional Franchise Head, International Markets AstraZeneca Singapore
A commercial leader with experience in Oncology and Cardiovascular therapeutic areas and worked across multiple geographies like Singapore, China, and Malaysia. Currently working in a regional role, he worked with a broad range of private and public stakeholders to tackle complex business challenges and elevate the patient experience across healthcare ecosystems.
Seminars
Wednesday 12th November 2025
SERENA-6: ctDNA-Guided Treatment Switch – A Potential New Paradigm in Cancer Management
2:25 pm
- Traditional approach to treating solid tumors uses radiology images to determine clinical progression, to switch treatment to control the disease
- SERENA-6 challenges that paradigm, using ctDNA serial monitoring to detect the emergence of ESR1 mutations in hormone receptor positive metastatic breast cancer (HR+ mBC)
- An early switch to camizestrant plus a CDK4/6 inhibitor upon ctDNA detection of ESR1 mutations during first-line therapy, significantly prolonged progression-free survival (PFS) versus the conventional approach of switching therapy at clinical progression (median PFS 16.0 vs 9.2 months at first interim analysis)
